Say Hello!
Don’t be shy.

   

News

XenoGesis has been acquired by leading drug discovery CRO, Sygnature Discovery, strengthening the combined DMPK offering and enhancing existing capabilities and expertise. This latest acquisition by Sygnature serves to meet the increasing demand for DMPK services and boosts the company’s reach into the pre-clinical space. XenoGesis’ novel...

Nottingham experts who designed new eyesight-saving technology are to launch more products which could speed up treatment while reducing the impact on hospital waiting lists and patient visits following COVID-19 restrictions. NuVision which is based at MediCity, Nottingham, has developed the designs from human amniotic membrane...

BioCity Nottingham based AdamsonJones has raised over £2,500 for The Friary and Alzheimer’s Society in a charity challenge with a difference. The East Midlands-based firm of patent and trade mark attorneys has successfully completed a challenge to collectively walk/run/cycle 750.5 miles to make a virtual journey...

Opportunity North East (ONE) is launching a new programme to help translate life sciences research and ideas into growth businesses that positively impact healthcare delivery and patient outcomes.   The programme of four 90-minute online workshops will help researchers, clinicians and potential entrepreneurs to start their commercialisation journeys.   ONE...

BioCity, Nottingham contract research organisation has appointed a new managing director. Barbara McManus has joined HistologiX which forms part of the Intelligent Tissue Group (ITG) alongside Tissue Solutions Ltd. McManus joined Tissue Solutions Ltd as its UK Biosample Project Manager in 2018. She said: "I’m looking forward to...

As AdamsonJones looks forward to celebrating 20 years in business on 1 August, we wish to thank all our staff, clients and colleagues for their ongoing commitment to intellectual property (IP) protection. Now more than ever we are grateful to be able to continue working...

X
X
X
X